Current approach to the diagnosis of atherosclerotic coronary artery disease: more questions than answers

Abstract

Despite its commonality in routine clinical practice, the approach to a diagnosis of atherosclerotic coronary artery disease remains complex and, in part, contentious. The traditional dogma linking ischaemia to hard clinical outcomes has been questioned and reframed over the years; rather than being a predictor of hard clinical outcomes, the degree of ischaemia may simply be a marker of atherosclerotic disease burden. A renewed interest in the imaging of plaque burden has spawned the contemporary role of CT imaging for not only diagnosis and prognosis, but also for dictating downstream management. As the technology develops and evidence expands, decisions on investigative modalities remain centred around patient factors, local availability, test performance and cost. This review summarizes the available methods for diagnosis in the symptomatic patient and provides an overview of the current evidence behind functional and anatomical approaches.

MicroRNA as a Novel Biomarker in the Diagnosis of Head and Neck Cancer

“…The first group consists of cardiovascular diseases, where the need for a new reliable marker is particularly high, as there is no gold standard for diagnosing these diseases so far. The existing markers show tissue specificity and require narrow time windows in the determinations, which often makes the obtained results unrecognizable or even false [28][29][30]. MiRNA seems to solve all these problems, hence the large-scale and advanced research towards its use as a biomarker in cardiovascular diseases [31][32][33][34].…”

Recent Advances of Cell Membrane Coated Nanoparticles in Treating Cardiovascular Disorders

“…For example, iodinated compounds are limiting in those with hypersensitivity or significant renal dysfunction. Gadolinium can also be limiting due to its potential toxicity in inducing nephrogenic systemic fibrosis, which is a rare but unmanageable scleroderma like disease [ 42 ].…”

The impact of lipid-lowering medications on coronary artery plaque characteristics

“…This evaluation can facilitate risk stratification and identify individuals who may benefit from intensification of therapy [12] . Such coronary artery atherosclerotic plaque assessment can be done by invasive or non-invasive techniques [ 13 , 14 ]. The benefits and limitations of various imaging techniques to evaluate coronary artery plaque are shown in Table 1 .…”